MacroGenics, Inc.
MacroGenics, Inc. (Nasdaq: MGNX) is a clinical-stage biopharmaceutical company developing antibody-based therapeutics, primarily for cancer. Its pipeline includes antibody-drug conjugates (ADCs) and multi-specific antibodies made with its DART and TRIDENT platforms; clinical-stage programs include lorigerlimab,… From the company’s description.
Over the twelve months to Jun 30, 2026, MacroGenics, Inc. reported revenue of $153.62M, down 7.2% from a year earlier, and a net loss of $14.59M. Its operating margin was −29.5%, and operations used $63.72M in cash. In fiscal 2025, it reported revenue of $149.50M, down 0.3% from fiscal 2024, and a net loss of $74.62M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MacroGenics, Inc. does
In the company’s own words
MacroGenics, Inc. (Nasdaq: MGNX) is a clinical-stage biopharmaceutical company developing antibody-based therapeutics, primarily for cancer. Its pipeline includes antibody-drug conjugates (ADCs) and multi-specific antibodies made with its DART and TRIDENT platforms; clinical-stage programs include lorigerlimab, MGC026, MGC028 and partnered candidate MGD024. The company also has preclinical programs and collaborates with biopharmaceutical partners on research, development and commercialization, retaining certain economic rights to partnered candidates and products. Three products originating from its pipeline have received FDA approval: ZYNYZ, marketed by Incyte; TZIELD, commercialized by Sanofi; and MARGENZA, whose global rights were sold to TerSera. MacroGenics operates a commercial-scale, FDA-approved antibody manufacturing facility in Maryland, producing drug substance for its clinical programs and commercial products, and providing contract development and manufacturing services to partners and other clients. Its proprietary antibody technologies include DART and TRIDENT, while its ADC programs use licensed linker-payload technologies. The company was founded in 2000.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- Rockville, MD
- Fiscal year end
- December
- CIK
- 1125345
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MacroGenics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MacroGenics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MacroGenics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MacroGenics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MacroGenics, Inc.'s last four quarterly filings that the numbers alone won't show?”